Bencyclane as an anti‐sickling agent

R. Koçak,F. Başlamışlı,B. Güvenc,L. Tamer,K. Aikimbaev,T. Isbir
DOI: https://doi.org/10.1046/j.1365-2141.1996.d01-1466.x
1996-01-01
British Journal of Haematology
Abstract:A vasodilating Ca2+ channel blocker, bencyclane, was used in 18 patients with homozygous sickle cell anaemia (SCD) to test the possible anti‐sickling effect. With bencylane intervention the Na+‐K+ ATPase activity increased from 256±29 to 331±37 nmol Pi/mg protein/h (P<0.0001) and the Ca2+‐Mg2+ ATPase level increased from 172±12 to 222±44 nmol Pi/mg protein/h (P<0.0001). The intracytoplasmic Ca2+ concentration reduced from 3.5±0.6 to 2.7±0.25 μmol/l (P<0.0001). The patient’s blood contained fewer irreversibly sickled cells (ISCs) (a reduction from 21.4% to 14.4%) (P<0.05). At the same time MCHC of the erythrocytes decreased from 34.5 to 33.0 g/dl (P<0.05). Bencyclane appears to be a promising anti‐sickling agent that can be used orally in SCD.
What problem does this paper attempt to address?